Drugs / GP MDI
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03358147 | Dec 2017 → Sep 2019 | asthma | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GP MDI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03358147 ↗ |
| Known as | PT001 | “GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID” NCT03358147 ↗ |
| Route | Inhaled | “GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID” NCT03358147 ↗ |